INDIVIOR INC.
RICHMOND, VA

The past two decades have been marked by strong growth and an expansion into more than 40 countries. While treatment for opioid use disorder has seen much innovation, we at Indivior are building on our intimate understanding of the patient journey to further advance addiction treatment including opiate overdose, alcohol use disorders, and co-occurring conditions such as schizophrenia by bringing to market We at Indivior are on an endeavor – one that is focused on individual patients around the world. Our name reflects this as the key words We aim to achieve this vision by living our patient-focused business model and adhering to the three pillars of our strategic plan: We will invest in innovating our market-leading products, discovering and developing new medications, and expanding patient treatment access infrastructure. We will accomplish this by: Engage with government, key opinion leaders, physicians, healthcare providers, payers, and patient advocacy groups to expand access to treatment and improve patient outcomes. We will help to improve patients’ lives by raising awareness and scientific understanding of the disease of the addiction and facilitating access to information and resources. We will do this by: Raise awareness and educate about addiction as a chronic, relapsing disease to help remove the stigma of addiction and encourage patients to seek treatment. Help patients take the first step on their journey by ensuring widely available, easy-to- access information and resource on treatments, healthcare providers, and disease management. A company rich in history, yet poised for the future. Indivior began with the goal of addressing the lack of treatment for the worldwide problem of addiction. In 1994, RB established the Buprenorphine Business Group, to which Indivior can trace its history of over 20 years. The buprenorphine Business Group focused on developing buprenorphine for the treatment of opioid dependence. Even though it was an area of business that was unproven, we believed we could make a measurable difference in the lives of patients all over the world. Through a grassroots effort, we’ve partnered with and educated governments, policy makers, payers, and healthcare professionals about diseases of addiction and the value of alternative treatment options (including office-based treatment). We’ve also worked diligently and strategically to identify and address the unmet treatment needs of patients. Prescribing information for Indivior products available upon request. Indivior History Highlights. Buprenorphine Business Group established by Reckitt Benckiser to develop buprenorphine for the treatment of opioid dependence February 2014, the Indivior entered into an agreement with AntiOp, Inc. to co-develop a naloxone nasal spray to aid in the reversal of opioid overdose with the option to acquire all rights to the product upon receipt of regulatory and marketing approval May 2014, Indivior entered into a global licensing agreement with XenoPort, Inc. for the development and commercialization of a clinical-stage oral product candidate called arbaclofen placarbil for the treatment of alcohol use disorder September - Indivior PLC incorporated December 23rd - Demerger of Reckitt Benckiser Pharmaceuticals Inc. from RB Group; listing as Indivior PLC on London Stock Exchange The Executive Committee is strong, experienced, and long-serving, with many years of industry experience and a long history with at the Indivior group. Each member is committed to the successful execution of our patient-focused business model while continuing to identify and address unmet market needs to drive growth. With extensive experience across industry sectors and in the addiction disease space, each member brings unique insights and perspectives to deliver Indivior’s vision. The transformation of addiction from a global human crisis to a recognized and treated disease worldwide must be thoughtfully navigated and guided by experience. Indivior’s board members provide a unique combination of business, scientific, pharmaceutical, and disease expertise—the most diverse set of experience and insight in the addiction space. This knowledge, coupled with a pioneering spirit, will be the catalyst to helping millions around the world reclaim their lives. Your help in reporting product concerns or adverse events plays a crucial role in our mission to ensure all patients have access to quality treatments. We take every opportunity to monitor patient safety with appropriate tools. For any safety related information, product complaints, to request medical information, if you have a product query or to report an adverse event please contact: This is our vision. We are Indivior and we will always focus on you. Product Query or Adverse Event If you or someone you know has experienced an adverse event to one of our treatments, please contact our staffed nurses who are prepared to help you. Product Query or Adverse Event If you or someone you know has experienced an adverse event to one of our treatments, please contact our staffed nurses who are prepared to help you.